HC Wainwright Reiterates “Buy” Rating for Longeveron (NASDAQ:LGVN)

Longeveron (NASDAQ:LGVN)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They currently have a $10.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 440.54% from the company’s current price.

LGVN has been the subject of a number of other reports. Roth Mkm began coverage on Longeveron in a report on Friday, December 6th. They set a “buy” rating and a $10.00 price target for the company. Roth Capital upgraded Longeveron to a “strong-buy” rating in a report on Thursday, December 5th.

Longeveron Stock Up 5.1 %

Shares of Longeveron stock opened at $1.85 on Friday. Longeveron has a 12-month low of $0.77 and a 12-month high of $6.40. The stock has a market capitalization of $27.62 million, a P/E ratio of -0.29 and a beta of 0.37. The stock has a 50 day moving average price of $1.60 and a two-hundred day moving average price of $1.84.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Jane Street Group LLC acquired a new position in shares of Longeveron in the fourth quarter valued at $35,000. Northern Trust Corp acquired a new position in shares of Longeveron in the fourth quarter valued at $31,000. Virtu Financial LLC acquired a new position in shares of Longeveron in the fourth quarter valued at $53,000. Geode Capital Management LLC raised its stake in shares of Longeveron by 316.0% in the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after purchasing an additional 97,953 shares in the last quarter. Finally, State Street Corp acquired a new position in shares of Longeveron in the third quarter valued at $29,000. 10.01% of the stock is currently owned by institutional investors and hedge funds.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.